To further improve the clinical outcome of EZH2 inhibitors, substantial in-depth investigation still needs to be performed to gain the comprehensive understanding of epigenetic regulation mediated by EZH2 in tumor cells. This evidence concerns the gene EZH2 and neoplasm.